Johan Bodegård

Johan Bodegård

AstraZeneca, Sweden - Södertälje / Sweden
Others
AD Scientific Index ID: 4400024
-
person_outline Johan Bodegård's MOST POPULAR ARTICLES
1-) Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative …M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ...Circulation 136 (3), 249-259, 20176232017
2-) Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 studyM Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ...Journal of the American College of Cardiology 71 (23), 2628-2639, 20183852018
3-) Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs …KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ...The lancet Diabetes & endocrinology 5 (9), 709-717, 20173312017
4-) Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl …F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ...Diabetes, Obesity and Metabolism 20 (2), 344-351, 20182292018
5-) Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD studyJ Sundström, J Bodegard, A Bollmann, MG Vervloet, PB Mark, A Karasik, ...The Lancet Regional Health–Europe 20, 20222152022